Gerardo Rosati

Summary

Publications

  1. ncbi Second-line chemotherapy with paclitaxel, cisplatin and gemcitabine in pre-treated sensitive cisplatin-based patients with advanced non-small cell lung cancer
    G Rosati
    Division of Medical Oncology, S Carlo Hospital, Potenza, Italy
    Anticancer Res 20:2229-33. 2000
  2. ncbi Elderly patients with advanced colorectal cancer: which therapy is the safest?
    Gerardo Rosati
    Medical Oncology Unit, S Carlo Hospital, Via P Petrone 1, 85100 Potenza, Italy
    Expert Opin Drug Saf 4:1041-9. 2005
  3. ncbi Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival
    Gerardo Rosati
    Medical Oncology Unit, S Carlo Hospital of Potenza, Potenza, Italy
    Tumour Biol 25:258-63. 2004
  4. ncbi Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?
    Gerardo Rosati
    Medical Oncology Unit, San Carlo Hospital, Potenza, Italy
    Nat Clin Pract Gastroenterol Hepatol 2:20-1. 2005
  5. ncbi A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer
    Gerardo Rosati
    Medical Oncology Unit, S Carlo Hospital of Potenza, Potenza, Italy
    Oncology 66:371-8. 2004
  6. ncbi Single-agent irinotecan as second-line weekly chemotherapy in elderly patients with advanced colorectal cancer
    Gerardo Rosati
    Medical Oncology Unit, S Carlo Hospital, Potenza, Italy
    Tumori 92:290-4. 2006
  7. ncbi Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: a phase II study
    Gerardo Rosati
    Medical Oncology Unit, S Carlo Hospital, Potenza, Italy
    Anticancer Res 23:2981-5. 2003
  8. ncbi An adrenal gland nodule presenting as an early sign of metastatic spread from colorectal cancer: report of two cases
    Gerardo Rosati
    Medical Oncology Unit, S Carlo Hospital, Potenza, Italy
    Tumori 93:103-5. 2007
  9. ncbi Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer: a phase II study
    G Rosati
    Medical Oncology Unit, S Carlo Hospital, Potenza
    Ann Oncol 18:vi128-32. 2007
  10. ncbi Responsiveness of skin metastases to CMF in a patient with urothelial carcinoma of the bladder: a case report
    Gerardo Rosati
    UO Oncologia Medica, Ospedale S Carlo, Potenza, Italy
    Tumori 89:85-7. 2003

Collaborators

Detail Information

Publications28

  1. ncbi Second-line chemotherapy with paclitaxel, cisplatin and gemcitabine in pre-treated sensitive cisplatin-based patients with advanced non-small cell lung cancer
    G Rosati
    Division of Medical Oncology, S Carlo Hospital, Potenza, Italy
    Anticancer Res 20:2229-33. 2000
    ..To investigate the safety and effectiveness of the combination of paclitaxel, cisplatin and gemcitabine as second-line in patients with advanced non-small cell lung cancer (NSCLC) sensitive to first-line cisplatin-based chemotherapy...
  2. ncbi Elderly patients with advanced colorectal cancer: which therapy is the safest?
    Gerardo Rosati
    Medical Oncology Unit, S Carlo Hospital, Via P Petrone 1, 85100 Potenza, Italy
    Expert Opin Drug Saf 4:1041-9. 2005
    ..However, some fit elderly patients seem to tolerate combination therapy reasonably well, whereas studies on unfit elderly subjects are needed...
  3. ncbi Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival
    Gerardo Rosati
    Medical Oncology Unit, S Carlo Hospital of Potenza, Potenza, Italy
    Tumour Biol 25:258-63. 2004
    ..However, further studies are needed to clarify the value of adopting biological prognostic factors into clinical practice...
  4. ncbi Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?
    Gerardo Rosati
    Medical Oncology Unit, San Carlo Hospital, Potenza, Italy
    Nat Clin Pract Gastroenterol Hepatol 2:20-1. 2005
  5. ncbi A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer
    Gerardo Rosati
    Medical Oncology Unit, S Carlo Hospital of Potenza, Potenza, Italy
    Oncology 66:371-8. 2004
    ..Patients and..
  6. ncbi Single-agent irinotecan as second-line weekly chemotherapy in elderly patients with advanced colorectal cancer
    Gerardo Rosati
    Medical Oncology Unit, S Carlo Hospital, Potenza, Italy
    Tumori 92:290-4. 2006
    ..A phase II study has reported significantly reduced toxicity when irinotecan was administered once a week for 2 weeks, followed by a week rest...
  7. ncbi Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: a phase II study
    Gerardo Rosati
    Medical Oncology Unit, S Carlo Hospital, Potenza, Italy
    Anticancer Res 23:2981-5. 2003
    ....
  8. ncbi An adrenal gland nodule presenting as an early sign of metastatic spread from colorectal cancer: report of two cases
    Gerardo Rosati
    Medical Oncology Unit, S Carlo Hospital, Potenza, Italy
    Tumori 93:103-5. 2007
    ..We present 2 cases that document examples of both events, so as to illustrate the most relevant aspects of this condition...
  9. ncbi Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer: a phase II study
    G Rosati
    Medical Oncology Unit, S Carlo Hospital, Potenza
    Ann Oncol 18:vi128-32. 2007
    ..A phase II study was conducted to evaluate the efficacy and safety of a combination regimen of a reduced dose intensity of docetaxel (Taxotere) plus capecitabine in pretreated patients with metastatic gastric cancer...
  10. ncbi Responsiveness of skin metastases to CMF in a patient with urothelial carcinoma of the bladder: a case report
    Gerardo Rosati
    UO Oncologia Medica, Ospedale S Carlo, Potenza, Italy
    Tumori 89:85-7. 2003
    ..The improvement in cutaneous lesions and pain reduction obtained prompt further exploration of the activity of this regimen in a second-line approach...
  11. ncbi Phase II trial of a biweekly regimen of fluorouracil and leucovorin plus irinotecan in patients with previously untreated advanced gastric cancer
    G Rosati
    Medical Oncology Unit, S Carlo Hospital, Potenza, Italy
    J Chemother 19:570-6. 2007
    ..03). Our data suggest that the biweekly regimen of LV and 5-FU plus CPT-11 in untreated patients with AGC is active and has an acceptable safety profile. Further evaluation of this regimen seems to be warranted in a phase III trial...
  12. pmc Role of chemotherapy and novel biological agents in the treatment of elderly patients with colorectal cancer
    Gerardo Rosati
    Medical Oncology Unit, S Carlo Hospital, Via P Petrone 1, Potenza 85100, Italy
    World J Gastroenterol 14:1812-22. 2008
    ..However, some fit elderly patients seem to tolerate combination therapy reasonably well, while studies on unfit elderly subjects are needed...
  13. pmc New perspectives in the treatment of advanced or metastatic gastric cancer
    Gerardo Rosati
    Medical Oncology Unit, S Carlo Hospital, Via P Petrone, Potenza 85100, Italy
    World J Gastroenterol 15:2689-92. 2009
    ..However, the biggest hope for significant survival advances in the near future would be the combination of new targeted biological agents with existing chemotherapy first-line regimens...
  14. ncbi A phase II study of irinotecan alternated with a weekly schedule of high-dose leucovorin and 48-hour 5-fluorouracil infusion in patients with metastatic colorectal cancer
    Gerardo Rosati
    Medical Oncology Unit, S Carlo Hospital, Potenza, Italy
    Oncology 62:209-15. 2002
    ....
  15. ncbi Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer
    G Rosati
    UO Oncologia Medica, Ospedale S Carlo Potenza, Nola Na, Italy
    Ann Oncol 12:669-74. 2001
    ....
  16. ncbi Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients
    Gerardo Rosati
    Medical Oncology Unit, S Carlo Hospital of Potenza, Italy
    Oncology 69:122-9. 2005
    ....
  17. doi XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study
    Gerardo Rosati
    Medical Oncology Unit, S Carlo Hospital, Potenza, Italy
    Cancer Chemother Pharmacol 71:257-64. 2013
    ..This phase II study was designed to evaluate the efficacy and safety of XELOX (capecitabine plus oxaliplatin) plus bevacizumab followed by bevacizumab alone in elderly patients with advanced CRC...
  18. doi Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: a retrospective Italian study
    Gerardo Rosati
    Medical Oncology Unit, S Carlo Hospital, Via P Petrone, 1, 85100, Potenza, Italy
    Invest New Drugs 30:1978-83. 2012
    ..Therefore the optimal duration of bevacizumab still remains undefined...
  19. ncbi Subcutaneous granulocyte-macrophage colony-stimulating factor in mucositis induced by an adjuvant 5-fluorouracil plus leucovorin regimen. A phase II study and review of the literature
    Antonio Rossi
    UO Oncologia Medica, Azienda Ospedaliera San G Moscati, Avellino, Italy
    Oncology 64:353-60. 2003
    ..To test the activity of subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF) administration in patients with colorectal cancer treated with adjuvant 5-fluorouracil (5-FU) plus leucovorin (LV) and suffering from mucositis...
  20. ncbi Stop Flow in abdominal and pelvic cancer relapses
    Rosario Vincenzo Iaffaioli
    Med Onc B INT Naples, Cagliari University, Italy
    Front Biosci 11:1284-8. 2006
    ..Stop-Flow is a safe and feasible technique very useful as a palliation treatment...
  21. pmc Supportive care in patients with advanced non-small-cell lung cancer
    M Di Maio
    National Cancer Institute Clinical Trials Unit, Naples
    Br J Cancer 89:1013-21. 2003
    ..Chemotherapy does not remarkably affect the pattern of SC, except for some drugs against side effects. Elderly patients assume more drugs for concomitant diseases and receive less antiemetics than adults...
  22. ncbi Carboplatin in combination with raltitrexed in recurrent and metastatic head and neck squamous cell carcinoma: A multicentre phase II study of the Gruppo Oncologico Dell'Italia Meridionale (G.O.I.M.)
    Domenico Galetta
    Medical and Experimental Department, Oncology Institute of Bari, Via Hanhemann 10, 70126 Bari, Italy
    Anticancer Res 25:4445-9. 2005
    ..Raltitrexed (R) is a potent and specific thymidylate synthase inhibitor with activity comparable to that of 5-FU in colorectal cancer; moreover, it showed activity as a single agent in HNSCC...
  23. ncbi First-line chemotherapy with fluorouracil and folinic acid for advanced colorectal cancer in elderly patients: a phase II study
    Bruno Daniele
    Medical Oncology, Clinical Trial Office, National Cancer Institute of Naples, Italy
    J Clin Gastroenterol 36:228-33. 2003
    ....
  24. ncbi Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II randomized study
    Francesco Caponigro
    Department of Medical Oncology A, Fondazione G Pascale, Naples, Italy
    Oncology 63:232-8. 2002
    ....
  25. ncbi "Misura" project: a retrospective survey on the use of 5fluorouracil in the treatment of colorectal cancer in 24 Italian clinical centers
    Paola Poletti
    Unita Operativa di Oncologia Medica, Ospedali Riuniti, Bergamo, Italy
    Tumori 88:104-9. 2002
    ..In palliative treatment a variety of schedules were administered by the Italian centers, lacking a standard therapy. There are very few surveys investigating oncology clinical practice. A larger survey on this issue is auspicable...
  26. ncbi Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale
    Giuseppe Colucci
    Medical and Experimental Oncology Unit, Oncology Institute, Via Amendola 209, 70126 Bari, Italy
    J Clin Oncol 23:4866-75. 2005
    ..We performed this phase III study to compare the irinotecan, leucovorin (LV), and fluorouracil (FU) regimen (FOLFIRI) versus the oxaliplatin, LV, and FU regimen (FOLFOX4) in previously untreated patients with advanced colorectal cancer...
  27. ncbi Single agent vinorelbine as first-line chemotherapy in elderly patients with advanced breast cancer
    Antonio Rossi
    U O Oncologia Medica, Azienda Ospedaliera S G Moscati, Via Circumvallazione, 68, 83100, Avellino, Italy
    Anticancer Res 23:1657-64. 2003
    ..The ELVIS (Elderly Lung cancer Vinorelbine Italian Study) trial demonstrated the tolerability and efficacy of VNR in elderly pts with advanced non-small cell lung cancer (JNCI 91: 66-72, 1999)...
  28. ncbi Primary gastric melanoma presenting as a double ulcer
    Domenico Germano
    J Clin Gastroenterol 38:828. 2004